DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Bone Marrow Failure
  4. Research Highlights/News
  5. 2024 Bone Marrow Failure Research Program

Bone Marrow Failure

NEWS RELEASE

Released: April 3, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Bone Marrow Failure Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Act provides funding for the Bone Marrow Failure Research Program (BMFRP) to support innovative, high-impact bone marrow failure research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 BMFRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

Applications submitted to the FY24 BMFRP must address one or more of the following Focus Areas:

  • Understand the causes and progression of bone marrow failure (BMF) diseases
  • Find effective BMF treatments and cures

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Development Award (IDA) Early Career Investigators:
Independent investigators at the level of Assistant Professor (or equivalent) with less than 10 years from their first faculty appointment (or equivalent)
or
Established Investigators:
Independent investigators at or above the level of Associate Professor (or equivalent) or an Assistant Professor (or equivalent) with 10 years or more from their first faculty appointment by the application submission deadline
  • Submission of a preproposal is required; application submission is by invitation only.
  • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
  • Research project should include well- formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach.
  • Hypothesis-generating correlative studies to existing clinical trials/studies are encouraged.
  • Translational potential should be considered and described.
  • May include relevant preliminary data.
  • Clinical trials are not allowed.
  • Maximum funding of $530,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years
Investigator-Initiated Research Award (IIRA) Independent Investigators at or above the level of Assistant Professor (or equivalent) by the application submission deadline
  • Submission of a preproposal is required; application submission is by invitation only.
  • Preliminary data are required.
  • Emphasis on Research Approach and Impact.
  • Clinical trials are not allowed.
  • Partnering Principal Investigator (PI) Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single project.
  • Different funding levels, based on the scope of research, are available. It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
Funding Level 1
Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in research, patient care, and/or quality of life in at least one of the FY24 BMFRP Focus Areas.
  • Correlative studies to existing clinical trials/studies are encouraged.
  • Translational potential should be considered and described.
Funding Level 2: Investigational New Drug (IND) application-enabling efforts
  • The proposed studies should be empirical in nature, product-driven, and focused on the accumulation of data to support an IND application to the U.S. Food and Drug Administration.
  • Applications are required to identify lead BMF therapy candidate(s) at time of submission, and transition plans should be considered and adequately described.
 Funding Level 1
  • Maximum funding of $675,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed 3 years

Funding Level 2: IND-enabling efforts

  • Maximum funding of $850,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://ebrap.org/ prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://ebrap.org/. For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Thursday, April 4, 2024